Eli Lilly takes aim at illicit market for its experimental weight-loss drug
The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.
Watch CBS News
The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.
The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.
The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month in some cases, officials said.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.
FDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Some popular medications are among those getting pricier at the start of 2024, including weight-loss drugs Ozempic and Mounjaro.
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Hanna, 76, first displayed symptoms of Alzheimer's in 2017.
Shares of the pharmaceutical company jumped almost 5% after announcing promising results for donanemab.
